Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21592
Title: New Advances in the Management of Cytomegalovirus in Allogeneic Haemopoietic Stem Cell Transplantation.
Authors: Yong, Michelle K;Gottlieb, David;Lindsay, Julian;Kok, Jen;Rawlinson, William;Slavin, Monica;Ritchie, David;Bajel, Ashish;Grigg, Andrew P
Affiliation: Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, New South Wales, Australia
Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, New South Wales, Australia
Pharmacy Department, Royal North Shore Hospital, New South Wales, Australia
Department of Haematology and Bone Marrow Transplantation, Westmead Hospital, Sydney, New South Wales, Australia
Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia
NSW Health Pathology, Prince of Wales Hospital, New South Wales, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: 12-Aug-2019
EDate: 2019-08-12
Citation: Internal medicine journal 2019; online first: 12 August
Abstract: Cytomegalovirus (CMV) viremia continues to be a frequent complication in the post haemopoietic stem cell transplant (HSCT) period despite a low incidence of CMV end-organ disease. A number of significant advances in the understanding and management of CMV infection have occurred in the last few years including improved diagnostics, monitoring of CMV immunity, availability of novel anti-CMV drugs, and emerging use of immunotherapies including CMV-specific T cell infusions. In addition to reviewing these advances we also explore some of the more practical prescribing issues of the older and newer CMV drugs including cost, toxicity and drug interactions to help clinicians navigate this new era of CMV management. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21592
DOI: 10.1111/imj.14462
ORCID: 0000-0002-8692-4145
0000-0002-4674-3403
PubMed URL: 31403736
Type: Journal Article
Review
Subjects: CMV immune monitoring
CMV-specific T cell therapy
Cytomegalovirus
haemopoietic stem cell transplantation
letermovir
maribavir
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.